Publikationen
Auszeichnung
Ende 2011 erhielt Professor Dr. Tino F. Schwarz von der international renommierten Fachzeitschrift „Vaccine“ (Impakt Faktor 3,467) eine Urkunde, mit der ihm und den Co-Autoren für eine im Jahr 2009 publizierte Arbeit gratuliert wurde. Der Beitrag gehörte zu den im Jahr 2009 meist zitiertesten Publikationen der Zeitschrift „Vaccine“. Die Publikationen finden Sie hier.
In dieser Studie, die im Herbst 2004 begann und 2014 endete, wurden die ersten Ergebnisse zur Immunogenität und Verträglichkeit des Impfstoffs gegen humane Papillomviren (Gebärmutterhalskrebs) bei Mädchen und Frauen im Alter 15-55 Jahren untersucht.
Die Ergebnisse der Studie zeigten, dass die Impfung in allen Altersklassen zu einer sehr guten Immunantwort führte. Die Verträglichkeit des Impfstoffs war unproblematisch. Im Jahr 2007 erfolgte die weltweite Zulassung dieses Impfstoffs, durch den sich zukünftig die Häufigkeit von bösartigen Tumoren im Anogenitalbereich von Frauen erheblich reduzieren lassen wird.
Übersichtsarbeiten
Schneider A, Schwarz TF, Hammerschmidt T, Siebert U: Einfluss einer Impfung gegen onkogene humane Papillomviren auf die Inzidenz und Mortalität von Zervixkarzinomen in Deutschland. Medizinische Klinik 102:515-523 (2007)
Pollmann H, Externest D, Ganser A, Eifrig B, Kreuz W, Lenk H, Pabinger I, Schramm W, Schwarz TF, Zimmermann R, Zavazava N, Oldenburg J, Klamroth R: Efficacy, safety and tolerability of recombinant factor VIII (Refacto) in patients with haemophlia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia 13:131-143 (2007)
Schmidt-Ott R, Schwarz TF, Haase R, Sander H, Walther U, Fourneau M, Htun-Myint L, Sänger R, Schuster V: Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years. Vaccine 26:32-40 (2007)
Schneider A, Schwarz TF, Hammerschmidt T, Rash RM, Siebert U. Vorgehen und Kosten bei der Abklärung und Behandlung unklarer und abnormaler zytologischer Befunde des Pap-Abstriches im Rahmen der Krebsfrüherkennungsuntersuchungen. Geburtshilfe und Frauenheilkunde 67:859-865 (2007)
Rumke HC, Bayas JM, de Juanes JR, Caso C, Richardus JH, Campins M, Rombo L, Duval X, Romanenko V, Schwarz TF, Fassakhov R, Abad-Santo F, von Sonnenburg F, Drame M, Sänger R, Ballou WR: Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults with a phase III safety trial. Vaccine 26:2378-2388 (2008)
Plentz A, Jilg W, Schwarz TF, Kuhr HB, Zent O: Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur® adults. Vaccine 27:853-856 (2009)
Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, Poncelet S, Zahaf T, Hardt K, Descamps D., Dubin G, on behalf of the HPV Study Group for Adult Women. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine 27:581-587 (2009)
Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter D, Kitchener H, Castellsague X, Teixeira TC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, for the HPV PATRICIA Study Group: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-314 (2009)
Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Dramé M, Gillarde P, Jilg W. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 27:6284-6290 (2009)
Garcia-Sicilia J, Schwarz TF, Carmona A, Peters K, Malkin JE, Tran PM, Behre U, Iturbe EB, Catteau G, Thomas F, Dobbelaere K, Descamps D, Dubin G for HPV Vaccine Adolescent Study Investigators Network. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine co-administered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women? Journal of Adolescent Health 46:142-151 (2010)
Schwarz TF, Kocken M, Petäjä T, Einstein MH, Spaczynski M, Louwers JA, Pedersen C, Levin M, Zahaf T, Poncelet S, Hardt K, Descamps D, Dubin G. Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccines 6:1054-1061 (2010)
Schwarz TF, Flamaing J, Rümke, HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC, Schmoele-Thomae B. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged =65 years. Vaccine 29:5195-5202 (2011)
Zollner U, Schwarz TF. Erkrankungen durch humane Papillomviren. Deutsche Medizinische Wochenschrift 136:1067-1072 (2011).
Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K, Poncelet S, Catteau G, Thomas F, Descamps D. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15–55 years. Human Vaccines 7:958-965 (2011).
Schwarz TF. Overview of clinical evidence: Cervarix. In: Franco E. Human papillomavirus vaccines. Future Medicine Ltd, 2011; doi: 10.2217/9781780840000, eISBN:978-1-78084-000-0, p.38-50
Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, Schuind A, Descamps D. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: results from a randomized study. Human Vaccines 7: 1374-1386 (2011).
Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SP, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Deschamps D, Struyf F, Dubin G, Lehtinen M for the HPV PATRICIA Study Group. Cross-protective efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types (PATRICIA randomized trial). Lancet Oncology 13:100-110 (2012)
Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, Skinner SR, Apter D, Naud P, Salmeron J, Chow SN, Kitchener H, Teixeira JC,Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, De Carvalho NS, Germar MJV, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Deschamps D, Struyf F, Dubin G, for the HPV PATRICIA Study Group. Overall efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia grade 3 or greater: end-of-study analysis of the randomized, double-blind PATRICIA trial. Lancet Oncology 13:89-99 (2012).
Pollmann H, Externest D, Ganser A, Eifrig B, Kreuz W, Lenk H, Pabinger I, Schramm W, Schwarz TF, Zimmermann R, Zavazava N, Oldenburg J, Klamroth R: Efficacy, safety and tolerability of recombinant factor VIII (Refacto) in patients with haemophlia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia 13:131-143 (2007)
Schmidt-Ott R, Schwarz TF, Haase R, Sander H, Walther U, Fourneau M, Htun-Myint L, Sänger R, Schuster V: Immunogenicity and reactogenicity of a trivalent influenza split vaccine in previously unvaccinated children aged 6-9 and 10-13 years. Vaccine 26:32-40 (2007)
Schneider A, Schwarz TF, Hammerschmidt T, Rash RM, Siebert U. Vorgehen und Kosten bei der Abklärung und Behandlung unklarer und abnormaler zytologischer Befunde des Pap-Abstriches im Rahmen der Krebsfrüherkennungsuntersuchungen. Geburtshilfe und Frauenheilkunde 67:859-865 (2007)
Rumke HC, Bayas JM, de Juanes JR, Caso C, Richardus JH, Campins M, Rombo L, Duval X, Romanenko V, Schwarz TF, Fassakhov R, Abad-Santo F, von Sonnenburg F, Drame M, Sänger R, Ballou WR: Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults with a phase III safety trial. Vaccine 26:2378-2388 (2008)
Plentz A, Jilg W, Schwarz TF, Kuhr HB, Zent O: Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur® adults. Vaccine 27:853-856 (2009)
Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, Poncelet S, Zahaf T, Hardt K, Descamps D., Dubin G, on behalf of the HPV Study Group for Adult Women. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine 27:581-587 (2009)
Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter D, Kitchener H, Castellsague X, Teixeira TC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, for the HPV PATRICIA Study Group: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-314 (2009)
Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Dramé M, Gillarde P, Jilg W. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 27:6284-6290 (2009)
Garcia-Sicilia J, Schwarz TF, Carmona A, Peters K, Malkin JE, Tran PM, Behre U, Iturbe EB, Catteau G, Thomas F, Dobbelaere K, Descamps D, Dubin G for HPV Vaccine Adolescent Study Investigators Network. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine co-administered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women? Journal of Adolescent Health 46:142-151 (2010)
Schwarz TF, Kocken M, Petäjä T, Einstein MH, Spaczynski M, Louwers JA, Pedersen C, Levin M, Zahaf T, Poncelet S, Hardt K, Descamps D, Dubin G. Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccines 6:1054-1061 (2010)
Schwarz TF, Flamaing J, Rümke, HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC, Schmoele-Thomae B. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged =65 years. Vaccine 29:5195-5202 (2011)
Zollner U, Schwarz TF. Erkrankungen durch humane Papillomviren. Deutsche Medizinische Wochenschrift 136:1067-1072 (2011).
Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K, Poncelet S, Catteau G, Thomas F, Descamps D. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15–55 years. Human Vaccines 7:958-965 (2011).
Schwarz TF. Overview of clinical evidence: Cervarix. In: Franco E. Human papillomavirus vaccines. Future Medicine Ltd, 2011; doi: 10.2217/9781780840000, eISBN:978-1-78084-000-0, p.38-50
Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, Schuind A, Descamps D. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: results from a randomized study. Human Vaccines 7: 1374-1386 (2011).
Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SP, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Deschamps D, Struyf F, Dubin G, Lehtinen M for the HPV PATRICIA Study Group. Cross-protective efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types (PATRICIA randomized trial). Lancet Oncology 13:100-110 (2012)
Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, Skinner SR, Apter D, Naud P, Salmeron J, Chow SN, Kitchener H, Teixeira JC,Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, De Carvalho NS, Germar MJV, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Deschamps D, Struyf F, Dubin G, for the HPV PATRICIA Study Group. Overall efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia grade 3 or greater: end-of-study analysis of the randomized, double-blind PATRICIA trial. Lancet Oncology 13:89-99 (2012).
Originalarbeiten
Schwarz TF: Human papillomavirus-16/18 candidate vaccine adjuvanted with AS04 and its impact on the incidence of cervical cancer. Expert Reviews in Obstetrics and Gynecology 2:293-303 (2007)
Schwarz TF. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Reviews in Vaccines. 7:1465-1473 (2008)
Schwarz TF, Oberdan L. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine. Improving upon nature. Gynecologic Oncology 110: S1-S10 (2008).
Schwarz TF. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix®. Advances in Therapy 26:983-998 (2009)
Schwarz TF. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Reviews in Vaccines. 7:1465-1473 (2008)
Schwarz TF, Oberdan L. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine. Improving upon nature. Gynecologic Oncology 110: S1-S10 (2008).
Schwarz TF. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix®. Advances in Therapy 26:983-998 (2009)